Luna Bioscience, Inc.

Westport, CT

UEI
HXZHX26PAUW5
CAGE
Not on record
Primary NAICS
Not on record
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Woman Owned Small Business
  • Woman Owned Business
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Similar vendors

About the company

Luna Bioscience, Inc., a woman-owned small business based in Westport, Connecticut, develops leptospirosis diagnostic assays and vaccines as a prime recipient of federal research grants from the National Institute of Allergy and Infectious Diseases (NIAID). The company operates exclusively in the federal grant space, with no contract prime or subcontract footprint; all four recent awards are NIAID Project Grants under CFDA 93.855 (Allergy and Infectious Diseases Research), totaling $3.3 million obligated across 2023 through 2026.

Luna Bioscience's grant portfolio centers on virulence-modifying (VM) protein-based diagnostics and vaccines targeting leptospirosis, a zoonotic bacterial infection affecting over one million people annually with a 5–20 percent case fatality rate. The company received a $901,305 Project Grant awarded September 24, 2025 (completing August 31, 2027) to develop solid-phase antibody-detection ELISA assays for rapid, point-of-care diagnosis of acute leptospirosis, with preliminary data showing detection of pathogen-specific IgM and IgG antibodies as early as four days post-infection in both experimentally infected macaques and naturally acquired human infections. A $300,239 Project Grant awarded July 14, 2026 (completing June 30, 2028) supports development of surrogate biomarkers for clinical trials of human leptospirosis vaccines, using purified IgG from vaccinated animals to benchmark VM protein-based vaccine candidates against lethal challenge in hamster models. Earlier work included a $901,305 Project Grant awarded May 7, 2024 (completing April 30, 2027) for leptospiral antigen-detection assays targeting rapid diagnosis, and a $1.2 million Project Grant awarded July 1, 2023 (completing June 30, 2025) focused on VM protein-based leptospirosis vaccine development. Work is performed in Westport, Connecticut across all awards. Three of the four awards face ultimate completion within the next twenty-four months, presenting recompete opportunity in the leptospirosis diagnostics and vaccine development pipeline at NIAID.

Quick answers

Is Luna Bioscience, Inc. registered in SAM.gov?

Yes. Luna Bioscience, Inc.'s SAM.gov registration is active through January 8, 2027.

What is Luna Bioscience, Inc.'s most recent federal award?

Luna Bioscience, Inc.'s most recent federal grant award is Development of surrogate biomarkers for supporting clinical trials of human leptospirosis vaccines - luna bioscience… (R41AI197598), from National Institute of Allergy and Infectious Diseases (NIH), on July 14, 2026.

On GovTribe

See Luna Bioscience, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors

Find teaming partners on GovTribe